We currently have to survey’s open for CML patients participation.
As an independent patient organization, we are actively gathering crucial patient insights on the use of Scemblix (Asciminib) for the treatment of Chronic Myeloid Leukemia (CML).
The Government of Canada is currently reviewing Scemblix to determine whether it should be approved as a frontline therapy for newly diagnosed CML patients. At present, Scemblix is approved in Canada only for patients who have failed treatment with two prior tyrosine kinase inhibitors (TKIs).
If you are a CML patient with firsthand experience using Scemblix, we invite you to share your valuable feedback. Your input will help ensure that patient experiences and perspectives are considered in this critical decision-making process.
🔗 Click the link below to participate. SCEMBLIX
✅ Eligibility:
Your voice matters in shaping the future of CML treatment. Thank you for your participation.
In collaboration with the TFR Group on Facebook, we are conducting a survey to gather essential insights from Chronic Myeloid Leukemia (CML) patients who are currently in Treatment-Free Remission (TFR) or have previously attempted TFR.
This survey aims to collect valuable data on patient needs, experiences, and treatment outcomes, helping us better understand the impact of TFR on the CML community.
🔹 Who Can Participate?
📌 Why Your Input Matters:
By participating, you will help shape future advocacy efforts, treatment strategies, and patient support initiatives. The findings will be compiled and shared with the community once a sufficient number of responses have been collected.
📩 How to Participate:
Follow the link below to complete the survey and ensure your voice is heard.
If you have any questions or require further information, please do not hesitate to reach out info@cmlsociety.org. Your participation is greatly appreciated and will contribute to ongoing efforts to improve care and outcomes for all CML patients.
